SYnAbs S.A.

SYnAbs was founded in 2015 as a Belgian spin-off of the Catholic University of Louvain (UCL), based on the work of Prof. Hervé Bazin, the inventor of the world`s first rat myeloma cell line. SYnAbs` vision is to fill the gap on the marketplace for innovative monoclonal antibodies against poor immunogenic compounds and complex homologous antigens. Targeting transmembrane proteins (GPCRs, ion channels, transporters), steroids, small molecules, toxins, lipids and polysaccharides (on fungi and bacteria), SYnAbs has developed a strong expertise in immunology to break immunotolerance in rat-LOU species to generate unique monoclonal antibodies of extreme specificity and higher affinity.